Kivorent News

Thursday, November 19, 2026

Health techNews

Siemens says FDA cleared its coronary plaque AI; the FDA letter is dated June

Siemens Healthineers announced on November 19 that the FDA cleared syngo.CT Coronary Cockpit, AI software that maps and measures plaque on coronary CT scans. The 510(k), K253786, was decided June 25.

Docket, covering health regulation and AI in care
, 3 min read

0.582agreement (Pearson r) on low-density plaque volume

What to know

  • The FDA cleared syngo.CT Coronary Cockpit through the 510(k) pathway (K253786) in a letter dated June 25, 2026, with Cleerly Labs as the predicate device.
  • Siemens tested the algorithm on 425 coronary CT angiography datasets from five U.S. states and three European countries; the summary reports no reader study or patient outcomes.
  • The clearance includes a predetermined change control plan that lets Siemens retrain the lumen and wall segmentation algorithm without a new 510(k).

The news that landed on November 19 is five months old by the FDA's own paperwork. Siemens Healthineers' syngo.CT Coronary Cockpit, which AuntMinnie and Diagnostic Imaging reported as newly cleared on Thursday, carries a 510(k) decision letter dated June 25, 2026. Nothing in that gap is improper; companies often wait for a trade show to announce. But it means the interesting reading isn't the press coverage, which gives no numbers. It's the 510(k) summary, which gives plenty.

What the software does, and what it is cleared to do

Coronary Cockpit reads coronary CT angiography (CCTA), the contrast-enhanced scan of the heart's arteries. It traces each vessel, segments the open channel (the lumen) and the vessel wall, then finds and measures plaque, sorting it into calcified, non-calcified, high-density and low-density deposits, per lesion or across the whole coronary tree. Siemens pitches it as support for choosing between medication and a stent, and for planning a stent procedure (percutaneous coronary intervention, or PCI) before the patient reaches the cath lab.

The FDA filed it as a Class II medical image management and processing system (product code QIH). It is a plug-in to Siemens' syngo.via reading software, not a standalone program. AuntMinnie reports that it works with CCTA from any scanner, with extra benefits on Siemens' dual-source and photon-counting machines; the company's December 2025 launch release described it only on those Siemens scanners.

The predicate, the device Siemens argued it is substantially equivalent to, is Cleerly Labs, a plaque-analysis product from a rival. That is how 510(k) works: you clear by resemblance, and the closest resemblance here was a competitor. The summary notes one thing the predicate lacks, treatment planning. (Our explainer on clearance versus approval covers why "cleared" is not "approved.")

The numbers in the summary

Siemens validated vessel tracing on 425 CCTA datasets from five U.S. states and three European countries. For vessels 1.5 mm or wider it reports 95.8% sensitivity and 96.1% precision against expert annotations, with no failed cases. Lumen and wall segmentation were checked on a random 150 of those cases, read twice by seven board-certified readers and adjudicated by two cardiologists.

The plaque figures are where the spread shows. Agreement with the expert reference (Pearson r) was 0.951 for calcified plaque volume, 0.727 for non-calcified, and 0.582 for low-density plaque. That is the weakest plaque result in the table, a long way from the 0.951 at the top of it. Diameter-based stenosis grading came in at 0.728.

What the summary does not contain: a reader study showing physicians do better with the tool, or any patient outcome. These are algorithm-against-annotation numbers, which is normal for this device class and worth knowing before anyone repeats Siemens' line that CCTA can more than halve referrals for diagnostic angiography. That claim, in the 2025 release, cites studies of CCTA on Siemens' Naeotom Alpha scanner, not of this software. (Our guide to reading a 510(k) summary explains what these sections can and cannot tell you.)

The change plan

The clearance includes a predetermined change control plan. It lets Siemens retrain the lumen and wall segmentation algorithm with more data and adjust its hyperparameters and processing without filing a new 510(k), as long as it follows the plan and tells users in release notes. The plaque measurements, the headline feature, are not named in that plan. Our PCCP explainer covers how those plans work; GE HealthCare's feeding-tube AI clearance this week is another imaging tool cleared on the same kind of evidence.

The open question is the other half of Siemens' pitch. In May the company described Coronary Cockpit as one end of a CT-to-cath-lab workflow with syngo PCI Connect, which was then pending FDA clearance. Neither Thursday's reports nor the FDA letter say whether that piece has cleared.

This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.

Sources

FDA and health regulationHeart health techDigital health and AI in care

Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.